Angus Bruno Reed

Angus Bruno Reed

Auto-generated profile, based on publicly available information

Angus Bruno Reed

Huma Therapeutics, London, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2021 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
SNShahram Nikbakhtian
Shahram Nikbakhtian
ARAngus B Reed
Angus B Reed
BOBernard Dillon Obika
Bernard Dillon Obika
DMDavide Morelli
Davide Morelli
ACAdam C Cunningham
Adam C Cunningham
DPDavid Plans
David Plans
Growing evidence suggests that poor sleep health is associated with cardiovascular risk. However, research in this area often relies upon recollection dependent questionnaires or diaries. Accelerometers provide an alternative tool for measuring sleep parameters objectively. This study examines the association between wrist-worn accelerometer-derived sleep onset timing and cardiovascular disease (CVD). We derived sleep onset and waking up time from accelerometer data collected from 103 712 UK Biobank participants over a period of 7 days. From this, we examined the association between sleep onset timing and CVD incidence using a series of Cox proportional hazards models. A total of 3172 cases of CVD were reported during a mean follow-up period of 5.7 (±0.49) years. An age- and sex-controlled base analysis found that sleep onset time of 10:00 p.m.–10:59 p.m. was associated with the lowest CVD incidence. An additional model, controlling for sleep duration, sleep irregularity, and established CVD risk factors, did not attenuate this association, producing hazard ratios of 1.24 (95% confidence interval, 1.10–1.39; P < 0.005), 1.12 (1.01–1.25; P = 0.04), and 1.25 (1.02–1.52; P = 0.03) for sleep onset <10:00 p.m., 11:00 p.m.–11:59 p.m., and ≥12:00 a.m., respectively, compared to 10:00 p.m.–10:59 p.m. Importantly, sensitivity analyses revealed this association with increased CVD risk was stronger in females, with only sleep onset <10:00 p.m. significant for males. Our findings suggest the possibility of a relationship between sleep onset timing and risk of developing CVD, particularly for women. We also demonstrate the potential utility of collecting information about sleep parameters via accelerometry-capable wearable devices, which may serve as novel cardiovascular risk indicators.

26 June 2021 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
PDF file
NDNikola Dolezalova
Nikola Dolezalova
ARAngus B Reed
Angus B Reed
ADAlex Jovan Despotovic
Alex Jovan Despotovic
BOBernard Dillon Obika
Bernard Dillon Obika
DMDavide Morelli
Davide Morelli
DPDavid Plans
David Plans
Aims: Cardiovascular diseases (CVDs) are among the leading causes of death worldwide. Predictive scores providing personalized risk of developing CVD are increasingly used in clinical practice. Most scores, however, utilize a homogenous set of features and require the presence of a physician. The aim was to develop a new risk model (DiCAVA) using statistical and machine learning techniques that could be applied in a remote setting. A secondary goal was to identify new patient-centric variables that could be incorporated into CVD risk assessments. Methods and results : Across 466 052 participants, Cox proportional hazards (CPH) and DeepSurv models were trained using 608 variables derived from the UK Biobank to investigate the 10-year risk of developing a CVD. Data-driven feature selection reduced the number of features to 47, after which reduced models were trained. Both models were compared to the Framingham score. The reduced CPH model achieved a c-index of 0.7443, whereas DeepSurv achieved a c-index of 0.7446. Both CPH and DeepSurv were superior in determining the CVD risk compared to Framingham score. Minimal difference was observed when cholesterol and blood pressure were excluded from the models (CPH: 0.741, DeepSurv: 0.739). The models show very good calibration and discrimination on the test data. Conclusion: We developed a cardiovascular risk model that has very good predictive capacity and encompasses new variables. The score could be incorporated into clinical practice and utilized in a remote setting, without the need of including cholesterol. Future studies will focus on external validation across heterogeneous samples.

10 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MDMohammad A. Dabbah
Mohammad A. Dabbah
ARAngus B. Reed
Angus B. Reed
ABAdam T.C. Booth
Adam T.C. Booth
AYArrash Yassaee
Arrash Yassaee
ADAlex Jovan Despotovic
Alex Jovan Despotovic
DMDiwakar Mohan
Diwakar Mohan
The COVID-19 pandemic has created an urgent need for robust, scalable monitoring tools supporting stratification of high-risk patients. This research aims to develop and validate prediction models, using the UK Biobank, to estimate COVID-19 mortality risk in confirmed cases. From the 11,245 participants testing positive for COVID-19, we develop a data-driven random forest classification model with excellent performance (AUC: 0.91), using baseline characteristics, pre-existing conditions, symptoms, and vital signs, such that the score could dynamically assess mortality risk with disease deterioration. We also identify several significant novel predictors of COVID-19 mortality with equivalent or greater predictive value than established high-risk comorbidities, such as detailed anthropometrics and prior acute kidney failure, urinary tract infection, and pneumonias. The model design and feature selection enables utility in outpatient settings. Possible applications include supporting individual-level risk profiling and monitoring disease progression across patients with COVID-19 at-scale, especially in hospital-at-home settings.

16 June 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AYArrash Yassaee
Arrash Yassaee
ARAngus Bruno Reed
Angus Bruno Reed
BSBen Swanson
Ben Swanson
ANAna Luísa Neves
Ana Luísa Neves
DHDougal Hargreaves
Dougal Hargreaves
Background: Disease-agnostic platforms (DAPs) are a digital health intervention (DHI) category that can support patients across multiple clinical conditions. While their versatility and configurability can address the fragmentation caused by condition-specific DHIs, DAPs present challenges for evaluation and certification, as they must be assessed across multiple therapeutic areas and diverse applications. A core challenge is identifying suitable evaluation frameworks that can accommodate the highly adaptable nature of this technology. Objective: This review explored whether there are suitable evaluation frameworks for the appraisal and subsequent certification of DAPs, whether any were applied in previous evaluations of DHIs and were available through open access (OA) publications. Methods: Twelve databases (PubMed, Embase, PsycINFO, MEDLINE, Scopus, Web of Science, ACMDL, IEEE Xplore, CINAHL, Cochrane Library, Compendex, and Business Source Complete) were searched on January 28, 2024. Titles, abstracts, and full texts were screened by 1 reviewer, with a minimum 10% sample dual-screened. Inclusion criteria included describing an evaluation framework applied to a DHI. Studies were excluded if there was no novel evaluation framework available to researchers, applicable to digital health evaluation domains, and applicable to a broad patient population. Evaluation frameworks identified were combined with those identified from 5 previous reviews, alongside handsearching and gray literature results. Each framework was assessed against essential and desirable criteria. Essential criteria were applicability across different therapeutic areas and populations, applicability to all domains of digital health, ability to support both formative and summative evaluation, and availability to researchers. Frameworks that met all essential criteria were assessed against desirable criteria, which included presence of operational guidance, evidence of considerations specific to digital health, and incorporation of an evidence assessment method. Results: A total of 40,907 search results contained 72 new frameworks. These were combined with 181 frameworks identified from previous reviews and 1 framework from handsearching and gray literature. Of the 254 frameworks assessed, 15 met all essential criteria, indicating potential suitability for DAP evaluation. One framework, the WHO (World Health Organization) guideline on monitoring and evaluating DHIs, met all desirable criteria. All suitable frameworks had been applied to DHIs and were available in at least 1 OA publication. Conclusions: We found that at least 15 existing frameworks appear suitable for DAP evaluation and can be used to benchmark DAPs against other DHIs. Limitations include potential bias from screening methods and underpinning reviews. Prior use of these frameworks in DHI evaluations and their availability in OA publications enables standardized, high-quality evaluation. Identification of suitable frameworks indicates that research efforts can focus on other outstanding questions related to DAP evaluation, including the acceptable performance benchmark for DAPs, the range of therapeutic areas DAPs need to be favorably evaluated in, and how to synthesize findings across multiple therapeutic areas. Trial Registration: OSF Registries 10.17605/OSF.IO/X578S; https://osf.io/x578s

28 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SNShahram Nikbakhtian
Shahram Nikbakhtian
ARAngus B Reed
Angus B Reed
BOBernard Dillon Obika
Bernard Dillon Obika
DMDavide Morelli
Davide Morelli
ACAdam C Cunningham
Adam C Cunningham
DPDavid Plans
David Plans
Aims: Growing evidence suggests that sleep quality is associated with cardiovascular risk. However, research in this area often relies upon recollection dependant questionnaires or diaries. Accelerometers provide an alternative tool for deriving sleep parameters measuring sleep patterns objectively. This study examines the associations between accelerometer derived sleep onset timing and cardiovascular disease (CVD). Methods and Results: We derived sleep onset and waking up time from accelerometer data collected from 103,712 UK Biobank participants over a period of seven days. From this, we examined the association between sleep onset timing and CVD incidence using a series of Cox proportional hazards models. 3172 cases of CVD were reported during a mean follow-up period of 5·7 (±0·49) years. An age- and sex-controlled base analysis found that sleep onset time of 10:00pm-10:59pm was associated with the lowest CVD incidence. A fully adjusted model, additionally controlling for sleep duration, sleep irregularity, and established CVD risk factors, was unable to eliminate this association, producing hazard ratios of 1·24 (95% CI, 1·10–1·39; p <0·005), 1·12 (1·01–1·25; p= 0·04), and 1·25 (1·02–1·52; p= 0·03) for sleep onset <10:00pm, 11:00pm-11:59pm, and ≥12:00am, respectively, compared to 10:00pm-10:59pm. Importantly, sensitivity analyses revealed this association was stronger in females, with only sleep onset <10:00pm significant for males. Conclusions: Our findings suggest an independent relationship between sleep onset timing and risk of developing CVD, particularly for women. We also demonstrate the potential utility of collecting information about sleep parameters via accelerometry-capable wearable devices, which may serve as novel cardiovascular risk indicators. Translational Perspective: Abnormal sleep timing is a feature of poor-quality sleep and is likely to be associated with cardiovascular diseases. Accelerometer-derived measures of sleep quality, particularly sleep timing, may be associated with greater vulnerability to cardiovascular disease, particularly in women. Onset of sleep timing may constitute a novel cardiovascular risk factor and target for preventative intervention. Wearable devices equipped with accelerometers may be useful in assessing sleep related cardiovascular disease risk factors as they would allow passive measurement of sleep parameters, such as sleep timing.

29 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MCMichele Colombo
Michele Colombo
NDNikola Dolezalova
Nikola Dolezalova
ADAlex Jovan Despotovic
Alex Jovan Despotovic
ARAngus B. Reed
Angus B. Reed
DMDavide Morelli
Davide Morelli
DPDavid Plans
David Plans
Background All-cause mortality (ACM) scores are a useful tool for identifying individuals with decreased life expectancy. An interpretable score consisting of smartphone-obtainable variables could allow for long-term management of individual health and support the next generation of healthcare monitoring and preventative practices. The aim of this study was to develop a 10-year ACM risk score using the UK Biobank dataset, using only digitally-obtainable variables. Methods The models were developed using the full UK Biobank cohort comprising nearly 500,000 individuals. We extracted 399 features from the dataset and, through a data-driven feature selection process with subsequent clinical review, identified 34 features for the final model. As part of the study, we compared two survival analysis approaches: Cox proportional hazards model and DeepSurv, a deep learning-based survival analysis algorithm. Results Before feature selection, Cox performed similarly to DeepSurv, achieving a c-index of 0.771 (95% CI 0.770–0.772) and 0.774 (95% CI 0.772–0.775) on the test dataset, respectively. Using the selected 34 features, the c-index of Cox decreased slightly to 0.770 (95% CI 0.769–0.770) and DeepSurv to 0.758 (95% CI 0.755–0.762). The models show excellent calibration at 10 years. Conclusions This study improves on a previous smartphone-compatible score, C-Score, by incorporating non-modifiable factors in addition to variables which can be actively modified to reduce risk. This score is comprehensive, easily interpretable and actionable, and as such, could provide a powerful tool for preventative healthcare.